PCSK9 inhibition: ready for prime time in CKD?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29792269.
- Also identified by DOI 10.1016/j.kint.2018.01.030.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lowering LDL cholesterol reduces the risk of atherosclerotic vascular disease in a wide range of patients with chronic kidney disease, with no evidence of a threshold below which further reductions no longer reduce risk. Statins safely lower LDL cholesterol, but novel inhibitors of proprotein convertase subtilisin kexin 9 (PCSK9) provide additional reductions which may reduce atherosclerotic vascular disease yet further in this high risk population.
Medical subject headings
- Cholesterol, LDL
- Proprotein Convertase 9